news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

On July 23, Shanghai Desano Pharmaceuticals Group Co., Ltd. and Chongqing Kangfude Pharmaceuticals Co., Ltd. signed an agreement to jointly build a peptide drug raw material and preparation production base in Banan District, Chongqing. Kangfude Pharmaceuticals received an investment of 120 million yuan from Desano Pharmaceuticals to be used for the construction of the entire peptide industry chain of its subsidiary Chongqing Xingtaihao Pharmaceutical Co., Ltd., to help Chongqing International Biocity compete in the new track of peptide drugs and make efforts in multiple areas to cultivate new quality productivity of biopharmaceuticals.

It is reported that Shanghai Desano Pharmaceuticals Group is an important supplier of world-renowned anti-AIDS raw materials and preparations. It is one of the first companies in my country to engage in the development of anti-AIDS drugs and obtain production approval. It has large-scale production capabilities for multiple series and dozens of varieties in the fields of antiviral, steroid and other drug raw materials. Among them, AIDS treatment drugs and antimalarial drug series drug raw materials occupy an important position in the global generic drug raw material market.

Chongqing Xingtaihao Pharmaceutical Co., Ltd., a subsidiary of Kangfude Pharmaceutical, is located in Chongqing International Biocity and mainly produces taxanes and other highly active and highly toxic anti-tumor APIs. Its representative products, such as paclitaxel, docetaxel, cabazitaxel, and eribulin (known as the Mount Everest in the field of chemical synthesis and one of the most expensive APIs in the world), have been supplied to many well-known pharmaceutical companies at home and abroad. It can provide customized CDMO services for APIs with high technical difficulty and long synthesis routes, and is committed to becoming the most reliable supplier in the global pharmaceutical supply chain.

The 120 million yuan investment will be used to build the entire industry chain of peptide drugs of Xingtai Hao Pharmaceutical. This is the second time that the company has been favored by the leading domestic anti-AIDS API companies after receiving strategic financing of over 100 million yuan from many well-known investment institutions such as Kangcheng Investment and Zhenjin Investment. It reflects the full recognition of the strategic layout of Xingtai Hao Pharmaceutical with peptides, high-activity APIs, and ADC compounds (linkers and payloads) as the main products. It is also the continued optimism of industrial investors and professional capital on the business environment and corporate development potential of Chongqing International Biocity. In the next step, Xingtai Hao Pharmaceutical will accelerate the construction of peptide drug production workshops and professional R&D pipelines that meet the international mainstream GMP standards of China, the United States, the European Union, etc. It is expected that after production, it will be able to mass-produce 5-7 peptide products such as semaglutide, telpotide, and retalutide, with an annual full-load capacity of about 1 ton, reaching the domestic leading level.

As the "1" core park of the "1+5+N" layout system of Chongqing's biopharmaceutical industry, in recent years, Chongqing International Biocity has been focusing on building a "1+3+N" pharmaceutical industry system with biological drugs as the core and chemical drugs, modern Chinese medicine, and medical devices as the characteristics, constantly expanding new industrial tracks and seizing the commanding heights of development. At present, the park's high-end biological drug fields such as vaccines, insulin, and antibody drugs have gathered domestic leading companies such as Zhixiang Jintai, Chen'an Bio, and Bowei Bio, with 57 innovative drugs under research, of which 25 have entered clinical trials and 10 have entered Phase III clinical trials, forming a unique development advantage in the western region. This time, Xingtaihao Pharmaceutical's investment in Deseno Pharmaceuticals will lay a more solid foundation for Chongqing International Biocity to compete in the new track of peptide drugs and continuously enrich its product pipeline.

At the signing ceremony, a plaque unveiling ceremony for Desano Pharmaceuticals' Western China Headquarters was also held. Desano Pharmaceuticals will rely on the Western China Headquarters to accelerate the substantive cooperation with Kangfude Pharmaceuticals, and in line with the company's development strategy, it will deploy projects such as the settlement center and high-quality drug industrialization base in Chongqing International Biocity to continue to strengthen its western business segment.

Upstream News Tan Ke Intern Cui Can